e23001 Background: Anemia is an extremely common and robustly deleterious complication experienced by patients with cancer, with impacts ranging from patient-reported quality-of-life metrics, to functional capacity, to morbidity and mortality implications. Cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) arise from a complex pathogenesis and are often associated with multifactorial etiology, but iron deficiency (ID) is an especially prominent genesis in these patients and is a preeminent clinical focus for hematology/oncology clinicians, not only because of its frequency, but also because it is directly treatable and reversible. Recent positive data readouts examining intravenous iron as a mechanism to improve anemia outcomes in comorbid oncologic states illustrates a compelling and exigent need to educate the hematology/oncology clinicians managing patients with cancer. These clinicians are optimally positioned to ensure improved CRA/CIA patient outcomes. That was the formative objective of this educational initiative. Methods: We conducted a 180-minute symposium at the 2021 American Society of Hematology (ASH) Annual Meeting, with a panel of 5 hematology/oncology experts. The activity was delivered live, in-person in Atlanta, and was also live streamed to a national and international audience on a virtual basis; the session was then provided as an online on-demand offering for those couldn’t attend the live meeting. Clinician knowledge metrics were evaluated from pre-activity to post-activity via audience response software (in-person) and Zoom polling (virtual); all test questions were directly correlated with activity learning objectives. Results: Across all 3 delivery modalities, the educational initiative reached a vast audience of nearly 8,000 learners. Meaningful knowledge advancements were achieved across each of the following clinical topics of emphasis (statistics reflect differential between pre-test and post-test performance): Diagnosis of CRA/CIA using clinical signs, symptoms, and laboratory diagnoses (+17%). Differentiation of functional vs. absolute iron deficiency (+33%). Identifying how elevated hepcidin levels impact iron supplementation strategies (+37%). Knowledge of improved safety profiles of next-generation IV iron products (+75%). Correctly evaluating the benefits of IV iron given a real-world CIA patient case (+33%). Conclusions: Our outcomes illustrate both the relatively low baseline knowledge of hematology/oncology clinicians related to CRA/CIA management and the transformative impact of timely educational programming. Ongoing educational efforts focused on this clinical topic and target audience are warranted.